Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976579 | 0.98 | MAOB (0.52) | MAOBMAP4K4PIM1ALDH1A1MAPT | |
| SCHEMBL1981584 | 0.84 | GAA (0.41) | MAOBPIM1ALDH1A1MAPTMAPK1 | |
| SCHEMBL1976842 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MAPK1TDP1KDM4EGAA | |
| SCHEMBL1977923 | 0.72 | MAOB (0.51) | MAOBMAP4K4PIM1ALDH1A1MAPT | |
| SCHEMBL12557889 | 0.71 | MAOB (0.61) | MAOBMAP4K4PIM1ALDH1A1KDM4E | |
| SCHEMBL9774731 | 0.71 | MAOB (0.61) | MAOBMAP4K4PIM1ALDH1A1MAPT | |
| SCHEMBL14693864 | 0.70 | MAOB (1.00) | MAOBALDH1A1MAPTKDM4EGAA | |
| SCHEMBL14693727 | 0.70 | MAOB (1.00) | MAOBALDH1A1MAPTKDM4EGAA | |
| SCHEMBL12557884 | 0.69 | MAOB (0.60) | MAOBMAP4K4PIM1ALDH1A1MAPT | |
| SCHEMBL14693975 | 0.68 | MAOB (1.00) | MAOBALDH1A1MAPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318402-B1 | Pyrrolidinyl-alkyl-amide derivatives their preparation and their therapeutic application as CCR3 receptor ligands | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8420636-B2 | Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as CCR3 receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20110144104-A1 | PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | MAOB 4722/4885MAP4K4 3129/4885PIM1 3833/4885 |
| US-20110144104-A1 | PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS | CCR3, CCR1, CCR4 | MAOB 4591/4885MAP4K4 2543/4885PIM1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.